Caplin Point Laboratories Limited (CAPLIPOINT.NS)
INR 1876.1
(-0.15%)
INR 1876.1
(-0.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.18 Billion INR | 10.93% |
| 2022 | 4.97 Billion INR | 14.93% |
| 2021 | 4.33 Billion INR | 23.3% |
| 2020 | 3.52 Billion INR | 18.52% |
| 2019 | 3.02 Billion INR | 20.75% |
| 2018 | 2.5 Billion INR | 20.13% |
| 2017 | 1.94 Billion INR | 50.92% |
| 2016 | 1.34 Billion INR | 69.31% |
| 2015 | 904.43 Million INR | 28.81% |
| 2014 | 619.98 Million INR | 57.56% |
| 2013 | 399.09 Million INR | 79.39% |
| 2012 | 238.52 Million INR | 100.91% |
| 2011 | 109.17 Million INR | 16.94% |
| 2010 | 93.36 Million INR | 42.01% |
| 2009 | 65.74 Million INR | 30.38% |
| 2008 | 50.42 Million INR | 39.52% |
| 2007 | 36.14 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.51 Billion INR | 4.83% |
| 2023 Q2 | 1.57 Billion INR | 13.91% |
| 2023 Q3 | 1.59 Billion INR | 0.98% |
| 2023 Q4 | 1.45 Billion INR | -8.94% |
| 2023 Q1 | 1.38 Billion INR | 2.39% |
| 2023 FY | - INR | 10.93% |
| 2022 Q2 | 1.22 Billion INR | 5.11% |
| 2022 Q4 | 1.35 Billion INR | 9.62% |
| 2022 FY | - INR | 14.93% |
| 2022 Q1 | 1.16 Billion INR | 4.19% |
| 2022 Q3 | 1.23 Billion INR | 1.21% |
| 2021 Q1 | 1.01 Billion INR | 7.0% |
| 2021 Q2 | 1.09 Billion INR | 7.7% |
| 2021 Q3 | 1.1 Billion INR | 0.77% |
| 2021 Q4 | 1.11 Billion INR | 0.86% |
| 2021 FY | - INR | 23.3% |
| 2020 Q1 | 780.9 Million INR | 14.8% |
| 2020 Q2 | 891.9 Million INR | 14.21% |
| 2020 Q4 | 951.59 Million INR | 6.03% |
| 2020 Q3 | 897.5 Million INR | 0.63% |
| 2020 FY | - INR | 18.52% |
| 2019 Q4 | 680.23 Million INR | -12.91% |
| 2019 Q1 | 718.49 Million INR | 15.53% |
| 2019 Q2 | 780.09 Million INR | 8.57% |
| 2019 FY | - INR | 20.75% |
| 2019 Q3 | 781.06 Million INR | 0.12% |
| 2018 Q1 | 546.39 Million INR | 5.85% |
| 2018 Q3 | 654.97 Million INR | 4.3% |
| 2018 Q4 | 621.93 Million INR | -5.05% |
| 2018 FY | - INR | 20.13% |
| 2018 Q2 | 627.98 Million INR | 14.93% |
| 2017 Q3 | 531.16 Million INR | 0.33% |
| 2017 Q1 | 497.61 Million INR | 4.46% |
| 2017 FY | - INR | 50.92% |
| 2017 Q4 | 516.17 Million INR | -2.82% |
| 2017 Q2 | 529.39 Million INR | 6.39% |
| 2016 Q1 | 238.33 Million INR | 7.84% |
| 2016 FY | - INR | 69.31% |
| 2016 Q4 | 476.36 Million INR | 40.11% |
| 2016 Q3 | 340 Million INR | -3.28% |
| 2016 Q2 | 351.54 Million INR | 47.5% |
| 2015 Q1 | 196.94 Million INR | 22.54% |
| 2015 Q2 | 216.5 Million INR | 9.93% |
| 2015 Q4 | 221.01 Million INR | -7.44% |
| 2015 FY | - INR | 28.81% |
| 2015 Q3 | 238.79 Million INR | 10.3% |
| 2014 Q2 | 126.38 Million INR | 2.56% |
| 2014 Q3 | 135.85 Million INR | 7.49% |
| 2014 FY | - INR | 57.56% |
| 2014 Q1 | 123.22 Million INR | 9.16% |
| 2014 Q4 | 160.71 Million INR | 18.3% |
| 2013 Q2 | 108.89 Million INR | 169.89% |
| 2013 Q4 | 112.87 Million INR | 7.95% |
| 2013 FY | - INR | 79.39% |
| 2013 Q1 | 40.34 Million INR | -26.85% |
| 2013 Q3 | 104.56 Million INR | -3.98% |
| 2012 Q2 | 48.73 Million INR | 1415.36% |
| 2012 Q1 | 3.21 Million INR | -90.67% |
| 2012 Q4 | 55.15 Million INR | -26.57% |
| 2012 FY | - INR | 100.91% |
| 2012 Q3 | 75.11 Million INR | 54.12% |
| 2011 Q2 | 28.35 Million INR | 0.0% |
| 2011 FY | - INR | 16.94% |
| 2011 Q4 | 34.46 Million INR | 0.98% |
| 2011 Q3 | 34.12 Million INR | 20.34% |
| 2010 FY | - INR | 42.01% |
| 2009 FY | - INR | 30.38% |
| 2008 FY | - INR | 39.52% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 9.879% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -807.253% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -47482.333% |
| FDC Limited | 3.38 Billion INR | -82.662% |
| Gufic Biosciences Limited | 1.48 Billion INR | -317.687% |
| Hikal Limited | 2.69 Billion INR | -129.691% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -137.236% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2051.448% |
| Medico Remedies Limited | 129.09 Million INR | -4690.153% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -302.699% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -2610.125% |
| RPG Life Sciences Limited | 1.28 Billion INR | -382.544% |
| Sequent Scientific Limited | 549.8 Million INR | -1024.736% |
| Shilpa Medicare Limited | 2.58 Billion INR | -138.943% |
| Sigachi Industries Limited | 883.39 Million INR | -600.002% |
| Themis Medicare Limited | 562.6 Million INR | -999.133% |
| Unichem Laboratories Limited | 742.35 Million INR | -732.997% |
| Venus Remedies Limited | 711.8 Million INR | -768.754% |
| Wanbury Limited | 985.49 Million INR | -527.485% |
| ZIM Laboratories Limited | 462.09 Million INR | -1238.204% |
| Lupin Limited | 36.96 Billion INR | 83.273% |
| Innova Captab Limited | 1.66 Billion INR | -270.663% |
| Ind-Swift Limited | 1.06 Billion INR | -480.603% |
| Bajaj HealthCare Limited | 406.23 Million INR | -1422.211% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 89.992% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 319.136% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -162.381% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -3434.691% |
| Morepen Laboratories Limited | 1.72 Billion INR | -258.283% |
| Laurus Labs Limited | 8 Billion INR | 22.76% |
| Aarti Drugs Limited | 3.24 Billion INR | -90.351% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 9.895% |
| Alembic Limited | 1.11 Billion INR | -453.935% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 35.697% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 45.487% |
| Vaishali Pharma Limited | 31.71 Million INR | -19400.489% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -58.177% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -1811.767% |
| Jubilant Pharmova Limited | 8 Billion INR | 22.76% |
| Eris Lifesciences Limited | 6.98 Billion INR | 11.489% |
| Windlas Biotech Limited | 781.72 Million INR | -691.051% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 95.531% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -360.336% |
| Orchid Pharma Limited | 1.41 Billion INR | -335.731% |
| Albert David Limited | 1.04 Billion INR | -491.512% |
| Hester Biosciences Limited | 539.47 Million INR | -1046.273% |
| Sakar Healthcare Limited | 393.26 Million INR | -1472.414% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -32.212% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -101.138% |
| Divi's Laboratories Limited | 25.43 Billion INR | 75.683% |
| Mankind Pharma Limited | 28.09 Billion INR | 77.989% |
| Neuland Laboratories Limited | 4.74 Billion INR | -30.235% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 33.755% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 89.001% |
| Wockhardt Limited | 1.08 Billion INR | -472.574% |
| Bal Pharma Limited | 345.59 Million INR | -1689.335% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 92.995% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -318.098% |
| Alkem Laboratories Limited | 24.19 Billion INR | 74.442% |
| Valiant Laboratories Limited | 12.73 Million INR | -48442.272% |
| Ajanta Pharma Limited | 12.56 Billion INR | 50.787% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -5296.787% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -13591.575% |
| Granules India Limited | 8.6 Billion INR | 28.127% |
| Medicamen Biotech Limited | 245.66 Million INR | -2417.219% |
| Ipca Laboratories Limited | 13.29 Billion INR | 53.504% |
| Brooks Laboratories Limited | 41.72 Million INR | -14719.306% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1337.171% |
| Piramal Enterprises Limited | -3.86 Billion INR | 260.156% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 82.337% |
| NATCO Pharma Limited | 18.79 Billion INR | 67.099% |
| Suven Life Sciences Limited | -992.78 Million INR | 722.877% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 7574.948% |
| Strides Pharma Science Limited | 3.76 Billion INR | -64.258% |
| Indoco Remedies Limited | 2.64 Billion INR | -133.611% |
| Alpa Laboratories Limited | 229.96 Million INR | -2589.065% |
| Lasa Supergenerics Limited | -65.08 Million INR | 9601.844% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 265.72% |